Compare EPR Properties (EPR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Summit Therapeutics Inc — how do they compare? EPR Properties trades at $54.74 (market cap $4.17B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 3.3× EPR Properties's market cap, and EPR Properties pays a 6.84% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 46 Days and Summit Therapeutics Inc for 16 Days on average.
| EPR | SMMT | |
|---|---|---|
Market Cap | $4.17B | $13.71B |
Volume | 992,716 | 6,173,057 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $26.38 |
52-Week Low | $48.71 | $12.43 |
Typical Hold Time | 46 Days | 16 Days |
Enterprise Value | $7.68B | $13.04B |
Dividend Yield | 6.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $54.74, up 1.22% today, with a bearish technical signal despite oversold RSI readings. The REIT reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Fundamentals show strong profitability with a 37.66% net income margin and a 6.5% dividend yield, supported by $421M in operating cash flow for 2025. Recent news highlights its appeal as a high-yield monthly dividend stock for retirees, with diversification into theme parks and fitness.
The outlook is cautiously optimistic, with a consensus price target of $65.50 implying 20% upside, though technical weakness and a projected net cash flow decline in 2026 pose risks. Investment opportunities include undervaluation relative to peers and resilient tenant performance, while risks involve interest rate sensitivity and execution of diversification strategy amid economic uncertainty.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
